Back to Feed
ClinicalTrials.gov|Clinical Trial
Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease
University of Colorado, Denver
Abstract
This trial will determine whether adding ruxolitinib to a reduced intensity conditioning (RIC) regimen reduces the rate of graft failure following haploidentical (haplo) hematopoietic cell transplant (HCT) for children and young adults with sickle cell disease (SCD). This study will enroll and treat up to 24 participants. Recruitment is expected to last for about 2 years and participants will be followed for an additional 2 years post-HCT. Phase: PHASE1, PHASE2 Status: RECRUITING Conditions: Sickle Cell Disease; Hematopoetic Stem Cell Transplant; Haploidentical Hematopoietic Stem Cell Transplant; Haploidentical Stem Cell Transplantation; Graft Failure Interventions: Ruxolitinib
Keywords
Sickle Cell DiseaseHematopoetic Stem Cell TransplantHaploidentical Hematopoietic Stem Cell TransplantHaploidentical Stem Cell TransplantationGraft Failure